Lisbeth Enggaard

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

Barbara Eichhorst, Carsten Utoft Niemann, Arnon P. Kater et al. · New England Journal of Medicine · 2023 · 268 citations · Full text

First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

Moritz Fürstenau, Arnon P. Kater, Sandra Robrecht et al. · The Lancet Oncology · 2024 · 59 citations · Full text

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial

Arnon P. Kater, Mark‐David Levin, Julie Dubois et al. · The Lancet Oncology · 2022 · 55 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Medicine +10

Real‐world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib

Kathrine Aarup, Emelie Curovic Rotbain, Lisbeth Enggaard et al. · European Journal Of Haematology · 2020 · 54 citations · Full text

Effects of live music during chemotherapy in lymphoma patients: a randomized, controlled, multi-center trial

Margrethe Langer Bro, Christoffer Johansen, Peter Vuust et al. · Supportive Care in Cancer · 2019 · 40 citations · Full text

Oncology, Lymphoma Patients, Multi-center Trial +3